20200303 BT-001 presentations EN
Category: 2020
First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
20200220 PR FPI 6002.03 EN
Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
20200107 PR TG4050 FPI – EN
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
https://www.transgene.fr/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
Transgene SITC 2019 Poster Jean-Baptiste Marchand et al. SITC 2019 Download the poster here Poster Presentation
